
    
      This is a Phase 1/2a, multicenter study, designed to evaluate the pharmacokinetics, safety,
      and tolerability of once daily administration of 150 mg of Ciprofloxacin for Inhalation (CFI)
      in patients with Cystic Fibrosis who have a history of chronic P. aeruginosa lung infection.
      Patients will be enrolled and followed in this study for 1 month. This study will consist of
      a Screening Phase, a Treatment Phase consisting of a 14 days, and a Follow up Phase
      consisting of a 14 days Off-treatment Period.
    
  